Corona vaccine update- How the Corona vaccine will go from one country to another? The coronavirus vaccine has already been applied in several countries. It will start in the European Union from December 27. Meanwhile, Asia’s countries are also getting ready.
It can be said that the initial push to make these vaccines against Covid-19 caused by coronavirus has been overcome. Pfizer and Moderna have already received approval from the US Food and Drug Administration (FDA). The Oxford University and AstraZeneca vaccines are expected to be approved this month. Vaccines from other countries of the world are also moving forward. But now the big obstacle is to get them to the country.
How the vaccine will reach different countries
The vaccine will arrive by air. That is by air. Products suppliers like UPS, DHL, and FedEx will play a big role here. Passenger airlines will also be involved. However, the big problem in transporting the vaccine is maintaining the required temperature.
The temperature required to preserve the vaccine
The Pfizer vaccine has to be stored at least -60 degrees Celsius, i.e. in ultra-cold storage. It is written in the website of the company that it cannot be kept in the common refrigerator for more than five days. And the Moderna vaccine can be stored for up to six months below zero in -20 degrees Celsius. It can be kept in the refrigerator for about a month. The Oxford University and AstraZeneca vaccines, however, have been reported to be kept at a temperature of 2 to 6 degrees Celsius.
Why the Oxford Vaccine Delay?
Corona vaccine update- December 8, 2020 will be remembered for two reasons. One is that on this day, after all the trials and formalities, Pfizer’s newly invented corona vaccine began to be applied to the public. On the same day, 91-year-old Margaret Kinan was vaccinated in Coventry, UK. This is the beginning of a global effort to control the Corona epidemic.
On this day, the results of the Phase-3 trial of the Oxford-AstraZeneca vaccine were published in the famous journal Lancet. As a result, adenovirus vector-dependent vaccines have been shown to be effective for the first time in history. The Oxford Vaccine is also the first corona vaccine to have its Phase 3 trial results published in a science journal. Earlier, Pfizer, Moderna, Russia’s Gamaleya and China’s Sinovac announced the interim results of Phase-3 trials of their vaccines through press briefings. However, no one has yet published the full results in any journal.
Oxford Vaccine Lancet Paper
This paper publishes the first interim results of the Oxford Vaccine Phase-3 trial. The safety profile of the vaccine has been confirmed by reviewing data from about 23,000 volunteers in the United Kingdom, Brazil and South Africa. However, data from a total of 11,636 volunteers in the United Kingdom and Brazil alone were reviewed to determine the effectiveness of the vaccine.
A review of the results showed that the vaccine’s effectiveness in vaccinating two full doses or standard doses (50 billion virus particles) was 62 percent. On the other hand, first half-dose or low-dose (22 billion virus particles) and then full dose vaccination gives 90 percent effectiveness. The average effectiveness of the Oxford vaccine is 72 percent. In other words, if every one hundred people are vaccinated, an average of 72 people will be saved from Covid.
Also, none of the vaccine recipients had severe covid-19, nor were any of them hospitalized. None of the vaccine recipients died. In other words, the Oxford vaccine protects people from severe covid. In this trial, ten people who were in the control group, that is, those who received the placebo or dummy vaccine, were hospitalized with covid. Two of them were infected with Severe Covid, one of whom died.
On the other hand, the Oxford vaccine has also been able to prevent asymptomatic corona infections. This immunosuppression is mainly observed in half-dose / full-dose vaccines of vaccines. While the two full doses of the vaccine prevent asymptomatic infections by only 4 percent, the half-dose / full-dose vaccine prevents infections by about 60 percent. This capability of the Oxford vaccine is expected to play a significant role in preventing the spread of infection. The ability of Pfizer or Moderna vaccines to prevent the spread of such infections has not yet been demonstrated.
What are the results of Oxford vaccine?
Corona vaccine update- All things considered, the results of the Oxford Vaccine Phase-3 trial seem to be quite good, but there are still some questions and complications. And this is why there may be some delay in the approval of the vaccine in the international market. For the past two weeks the British Regulatory Body (MHRA) has been reviewing the results of all clinical trials of the Oxford vaccine through a rolling review. It is unclear whether they will allow the vaccine to be used in an emergency. If you do, it will be for the UK. The US regulatory body, the FDA, and the World Health Organization have indicated that the interim results of the Phase-3 trial of the Oxford vaccine are not sufficient for approval at this time.